Revance raises $33m for topical Botox competitor
This article was originally published in Scrip
Executive Summary
After Revance Therapeutics bought out a competitor's option to acquire its needle-free alternative to Allergan's Botox (onabotulinumtoxinA) injections, the company has raised new venture capital so that it may proceed with late-stage development.